<DOC>
	<DOCNO>NCT03013946</DOCNO>
	<brief_summary>The primary objective trial determine effect 24-week concomitant coaching patient report outcomes patient receive standard treatment mRCC sunitinib .</brief_summary>
	<brief_title>Role PRoactivE Coaching PAtient REported Outcome Advanced Metastatic RCC Treated With Sunitinib</brief_title>
	<detailed_description>The goal study define benefit proactive coaching mRCC , compare reactive approach , consider standard care . Patients Coaching Arm A train continuously personal interaction coach patient ( Face-to Face meeting well telephone contact ) . The patient educate nature severity treatment emergent Adverse event ( TEAE ) Sunitinib-Therapy . Quality Life ( QoL ) assess sunitinib treatment arm ( Arm A Coaching Arm B non Coaching ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Written inform consent locallyrequired authorization ( EU Data Privacy Directive EU ) obtain subject prior performing protocolrelated procedure , include screen evaluation 2 . Age ≥ 18 year time study entry 3 . Advanced metastatic renal cell carcinoma , amendable surgery curative intent , render patient eligible Tyrosin Kinase Inhibitor ( TKI ) treatment sunitinib 4 . Intended firstline treatment sunitinib 5 . Documented progressive disease within 6 month prior study inclusion 6 . Patients measurable disease ( least one unidimensionally measurable target lesion CTscan MRI ) accord modify Response Evaluation Criteria Solid Tumors ( RECIST 1.1 ) well nonmeasurable disease eligible . 7 . Prior radiotherapy surgery allow complete 4 week ( minor surgery palliative radiotherapy bone pain : 2 week ) prior start treatment patient recover toxic effect . 8 . Female subject must either nonreproductive potential ( ie , postmenopausal history : ≥60 year old menses ≥1 year without alternative medical cause ; OR history hysterectomy , OR history bilateral tubal ligation , OR history bilateral oophorectomy ) must negative serum pregnancy test upon study entry . 9 . Subject willing receive additional concomitant coaching able comply QoL/PRO ( patientreported outcome ) assessment specify protocol duration study include schedule visit , examination follow . 1 . Any anticancer treatment aside sunitinib mRCC ( except palliative radiotherapy ) 2 . Previous malignancy ( mRCC ) either progress require active treatment . Exceptions : basal cell cancer skin , preinvasive cancer cervix , T1a T1b prostate carcinoma , superficial bladder tumor [ Ta , Tis T1 ] . 3 . CNS metastases , unless local therapy complete least 3 month patient require use steroid . 4 . Chronic liver disease ChildPugh B C score 5 . Female subject pregnant , breastfeed male female patient reproductive potential employ effective method birth control ( failure rate le 1 % per year ) 6 . Any condition , opinion investigator , would interfere evaluation concomitant coach QoL assessment interpretation patient safety study result 7 . Participation another clinical study investigational product last 30 day inclusion 8 . Any previous treatment tyrosine kinase inhibitor metastatic disease . Adjuvant neoadjuvant therapy localize disease permit , provide relapse occur least 6 month last exposure 9 . Previous enrollment randomization present study ( include screen failure ) . 10 . Involvement plan and/or conduct study ( applies Pfizer staff and/or staff sponsor study site ) 11 . Patient might affiliate otherwise dependent sponsor , site investigator 12 . Patient incarcerate involuntarily institutionalize court order authority [ § 40 Abs . 1 S. 3 Nr . 4 AMG ] . 13 . Patients unable consent understand nature , significance implication clinical trial therefore form rational intention light fact [ § 40 Abs . 1 S. 3 Nr . 3a AMG ] .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>